Patents Represented by Attorney, Agent or Law Firm John F. Levis
  • Patent number: 8349880
    Abstract: The present disclosure provides a series of compounds of the formula (I) which reduce ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: January 8, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lawrence R. Marcin, Lorin A. Thompson, III, Kenneth M. Boy, Jason M. Guernon, Mendi A. Higgins, Jianliang Shi, Yong-Jin Wu, Yunhui Zhang, John E. Macor
  • Patent number: 8252821
    Abstract: Pharmaceutical capsule compositions containing the active compound (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide, and polyethylene glycol (PEG), Vitamin E polyethylene glycol succinate, polyvinylpryrrolidone (PVP) or copovidone (PVP-Polyvinyl acetate), with or without citric acid, are provided.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: August 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sachin Chandran, Rajesh Babulal Gandhi, Jaquan Kalani Levons, Robert Kevin Perrone, Christopher P. Price, Krishnaswamy Srinivas Raghavan, Ismat Ullah
  • Patent number: 8242124
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: August 14, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alicia Regueiro-Ren, Jacob Swidorski, Zheng Liu, Tao Wang, Zhongxing Zhang, Lawrence G. Hamann, Nicholas A. Meanwell, David J. Carini, Wenying Li
  • Patent number: 8168615
    Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: May 1, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yasutsugu Ueda, Timothy P. Connolly, John F. Kadow, Nicholas A. Meanwell, Tao Wang, Chung-Pin H. Chen, Kap-Sun Yeung, Zhongxing Zhang, David Kenneth Leahy, Shawn K. Pack, Nachimuthu Soundararajan, Pierre Sirard, Kathia Levesque, Dominique Thoraval
  • Patent number: 8124615
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: February 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Yasutsugu Ueda, Lawrence G. Hamann, Zhongxing Zhang, Zhiwei Yin, Alicia Regueiro-Ren, David J. Carini, Jacob Swidorski, Zheng Liu, Barry L. Johnson, Nicolas A. Meanwell, John F. Kadow
  • Patent number: 8119389
    Abstract: The present invention relates to a process for preparing (2R,3S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butane comprising contacting a mutagenized Rhodococcus erythropolis having ATCC deposit no. PTA-6648 with (3S)-1-halo-2-oxo-3-(protected)amino-4-substituted butane substrate. The present invention also relates to a process comprising mixing (2R,3S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butane with at least one base in the presence of at least one solvent to produce a reaction mixture containing (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane. The present invention further relates to a process comprising crystallizing the (2R,3S)-1,2-epoxy-3-(protected)amino-4-substituted butane out of the reaction mixture by concurrently adding water and the reaction mixture together. The present invention is also directed to a mutagenized Rhodococcus erythropolis having ATCC deposit no. PTA-6648.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: February 21, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nigel Ian Bowers, Paul M. Skonezny, Gregory L. Stein, Thomas Franceschini, Shu-Jen Chiang, Wendy L. Anderson, Li You, Zizhuo Xing
  • Patent number: 8067420
    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R2, R3, R8, and R9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: November 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Philip D. Stein, Sharon N. Bisaha, Saleem Ahmad, Khehyong Ngu, William N. Washburn
  • Patent number: 8039486
    Abstract: This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: October 18, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Michelle E. Farkas, John F. Kadow, Nicholas A. Meanwell, Malcolm Taylor, David Johnston, Thomas Stephen Coulter, J. J. Kim Wright
  • Patent number: 7981913
    Abstract: There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: July 19, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lorin A. Thompson, III, Kenneth M. Boy, Jianliang Shi, John E. Macor
  • Patent number: 7977362
    Abstract: Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a ?-secretase enzyme; or (ii) the production of ?-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R1, and R2 are described herein.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: July 12, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, Zhaoxing Meng, Ivar M. McDonald, Richard E. Olson, John E. Macor
  • Patent number: 7968718
    Abstract: A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: June 28, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nachimuthu Soundararajan, Yuping Qiu, Wenhao Hu, David R. Kronenthal, Pierre Sirard, Jean Lajeunesse, Robert Droghini, Ramakrishnan Chidambaram, Xinhua Qian, Kenneth J. Natalie, Shawn K. Pack, Nathan Reising, Erqing Tang, Michael G. Fakes, Qi Gao, Feng Qian, Blisse J. Vakkalagadda, Chiajen Lai, Shan-Ming Kuang
  • Patent number: 7960406
    Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: June 14, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Yasutsugu Ueda, Lawrence G. Hamann, Zhongxing Zhang, Zhiwei Yin, Alicia Regueiro-Ren, David J. Carini, Jacob Swidorski, Zheng Liu, Barry L. Johnson, Nicholas A. Meanwell, John F. Kadow
  • Patent number: 7915283
    Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: March 29, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, John F. Kadow, Nicholas A. Meanwell, Kap-Sun Yeung, Zhongxing Zhang, Zhiwei Yin, Zhilei Qui, Daniel H. Deon, Clint A. James, Edward H. Ruediger, Carol Bachand
  • Patent number: 7902204
    Abstract: The invention comprises substituted diazaindole-dicarbonyl-piperazinyl derivatives of general Formula I wherein: Q is selected from the group consisting of -- may represent a bond; T is —C(O)— or —CH(CN)—; and —Y— is selected from the group consisting of compositions thereof and their use for treating HIV infection.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: March 8, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Zhong Yang, John F. Kadow, Nicholas A. Meanwell
  • Patent number: 7902218
    Abstract: There is provided a series of tetrahydroisoquinoline diaminopropane compounds of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R8 and R9 are as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by ?-secretase and, more specifically, inhibit the production of A?-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to ?-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: March 8, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lorin A. Thompson, III, Kenneth M. Boy, Jianliang Shi, John E. Macor, Andrew C. Good, Lawrence R. Marcin
  • Patent number: 7851476
    Abstract: Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine its salts and solvates thereof are herein set forth, as are pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: December 14, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chung-Pin H. Chen, Dawn DiGiugno Parker, Qi Gao, Chong-Hui Gu, Jaquan Kalani Levons, Bing-Shiou Yang
  • Patent number: 7829711
    Abstract: The instant invention provides crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione; processes for the production of such crystalline materials; pharmaceutical compositions comprising such crystalline materials; and methods of treating HIV or AIDS with such crystalline materials or such pharmaceutical compositions.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: November 9, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: John D. Matiskella, Chenkou Wei, Qi Gao, Chong-Hui Gu, Shan-Ming Kuang
  • Patent number: 7820820
    Abstract: A method of preparing azaindole compounds for antiviral use having the formula
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: October 26, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wansheng Liu, Sunil S. Patel, Nicolas Cuniere, Yvonne Lear, Prashant P. Deshpande, Jeffrey N. Simon, Chiajen Lai, Annie J. Pullockaran, Nachimuthu Soundararajan, Jeffrey T. Bien
  • Patent number: 7807676
    Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: October 5, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, John F. Kadow, Zhongxing Zhang, Zhiwei Yin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Jacob Swidorski, Ying Han, David J. Carini, Lawrence G. Hamann
  • Patent number: 7807671
    Abstract: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity useful for the treatment of HIV and AIDS.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: October 5, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, John F. Kadow, Zhongxing Zhang, Zhiwei Yin, Nicholas A. Meanwell, Alicia Regueiro-Ren, Jacob Swidorski, Ying Han, David J. Carini